BeyondSpring Announces Three Poster Presentations About its Chemotherapy-Induced Neutropenia Prevention Program at the European Society for Medical Oncology 2021 Congress
09 sept. 2021 07h00 HE
|
BeyondSpring, Inc.
Plinabulin in combination with G-CSF is undergoing regulatory review for potential approval in the U.S. and China for the prevention of CIN, with a U.S. PDUFA date of November 30, 2021. NEW YORK,...
BeyondSpring to Participate in the Upcoming September Conferences
08 sept. 2021 17h54 HE
|
BeyondSpring, Inc.
NEW YORK, Sept. 08, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (“BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today...
BeyondSpring to Host Second Quarter Financial Results and Corporate Update Conference Call on September 10, 2021
07 sept. 2021 08h00 HE
|
BeyondSpring, Inc.
NEW YORK, Sept. 07, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (“BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today...
BeyondSpring Announces Late-Breaking Oral Presentation of Final Phase 3 DUBLIN-3 Data with the Plinabulin/Docetaxel Combination Versus Docetaxel Alone in 2nd/3rd Line Non-Small Cell Lung Cancer Patients with EGFR Wild Type at the European Society for Medical Oncology 2021 Congress
31 août 2021 07h00 HE
|
BeyondSpring, Inc.
Topline results, released in early August, demonstrated improvement in overall survival (OS) for the combination vs. docetaxel alone as well as improvement in ORR, PFS, 24- and 36-month OS rates and...
BeyondSpring Announces Exclusive Commercialization and Co-development Agreement with Jiangsu Hengrui Pharmaceuticals for Plinabulin in Greater China
26 août 2021 07h00 HE
|
BeyondSpring, Inc.
Wanchunbulin, BeyondSpring’s 58%-owned subsidiary in China, to partner with Hengrui, the leader in oncology product R&D and commercialization in China, for the exclusive commercial and...
BeyondSpring CEO Dr. Lan Huang Named to PharmaVOICE 100 Most Inspiring People in Life Sciences
10 août 2021 08h00 HE
|
BeyondSpring, Inc.
Distinguished industry executive and entrepreneur recognized for the development of a first-in-class asset in the oncology space NEW YORK, Aug. 10, 2021 (GLOBE NEWSWIRE) -- BeyondSpring (the...
BeyondSpring Announces Positive Topline Results from its DUBLIN-3 Registrational Trial of Plinabulin in Combination with Docetaxel for the Treatment of 2nd/3rd Line Non-Small Cell Lung Cancer (NSCLC) with EGFR Wild Type
04 août 2021 07h00 HE
|
BeyondSpring, Inc.
Study met primary endpoint showing statistically significant improvement in overall survival (OS) for the combination vs. docetaxel.Study met key secondary endpoints showing statistically significant...
BeyondSpring Strengthens Board with the Addition of Ex-Immunomedics and Constellation Commercial Head Brendan Delaney
14 juil. 2021 07h30 HE
|
BeyondSpring, Inc.
NEW YORK, July 14, 2021 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global pharmaceutical company focused on the development of cancer therapeutics, today...
BeyondSpring to Participate in the William Blair Biotech Focus Conference
08 juil. 2021 08h00 HE
|
BeyondSpring, Inc.
NEW YORK, July 08, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (“BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today...
BeyondSpring to Host R&D Day to Discuss Novel Immune Agent Plinabulin’s Development Program in Anti-cancer Indications
17 juin 2021 16h00 HE
|
BeyondSpring, Inc.
NEW YORK, June 17, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer...